No Data
No Data
One Immunic Insider Raised Their Stake In The Previous Year
B.Riley Financial Maintains Immunic(IMUX.US) With Buy Rating, Maintains Target Price $6
Analysts' Top Healthcare Picks: Radnet (RDNT), Immunic (IMUX)
Immunic Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Immunic's Vidofludimus Calcium: A Promising MS Treatment With Dual Mechanism and Positive Trial Results Justifying Buy Rating
Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
dunbegreedy : volume!!! let's go